News from the FDA/CDC

As FDA OKs another COVID booster, some experts question need


 

Supply issues?

Meanwhile, the United Kingdom has begun offering boosters to anyone over 75, and Sweden’s health authority has recommended a fourth shot to people over age 80.

That puts pressure on the United States — at least on its politicians and policymakers — to, in a sense, keep up, said the infectious disease specialists.

Indeed, the White House has been keeping fourth shots in the news, warning that it is running out of money to ensure that all Americans would have access to one, if recommended.

On March 23, outgoing White House COVID-19 Response Coordinator Jeff Zients said the federal government had enough vaccine for the immunocompromised to get a fourth dose “and, if authorized in the coming weeks, enough supply for fourth doses for our most vulnerable, including seniors.”

But he warned that without congressional approval of a COVID-19 funding package, “We can’t procure the necessary vaccine supply to support fourth shots for all Americans.”

Mr. Zients also noted that other countries, including Japan, Vietnam, and the Philippines had already secured future booster doses and added, “We should be securing additional supply right now.”

Dr. Schaffner says that while it would be nice to “have a booster on the shelf,” the United States needs to put more effort into creating a globally-coordinated process for ensuring that vaccines match circulating strains and that they are manufactured on a timely basis.

He says he and others “have been reminding the public that the COVID pandemic may indeed be diminishing and moving into the endemic, but that doesn’t mean COVID is over or finished or disappeared.”

Dr. Schaffner says that it may be that “perhaps we’d need a periodic reminder to our immune system to remain protected. In other words, we might have to get boosted perhaps annually like we do with influenza.”

A version of this article first appeared on WebMD.com.

Pages

Recommended Reading

If you’ve never had COVID, should you relax or worry?
MDedge Psychiatry
Biden administration’s new test-to-treat program pits pharmacists against physicians
MDedge Psychiatry
New ACC guidance on cardiovascular consequences of COVID-19
MDedge Psychiatry
COVID surge in Western Europe puts U.S. health experts on alert
MDedge Psychiatry
‘Alarming’ worldwide decline in mental health
MDedge Psychiatry
U.S. health officials tracking COVID-19 increase in U.K.
MDedge Psychiatry
‘Profound implications’: COVID ups diabetes risk 40% a year later
MDedge Psychiatry
‘Pandemic brain’ not limited to patients infected with COVID-19
MDedge Psychiatry
Neuropsychiatric outcomes similar for hospitalized COVID-19 patients and non–COVID-19 patients
MDedge Psychiatry
‘Staggeringly high’ rates of psychiatric symptoms after COVID-19
MDedge Psychiatry